Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

People receiving haemodialysis for kidney failure frequently feel chronic pain associated with their disease, which can be ...

The US Food and Drug Administration (FDA) has approved a new pain medication, suzetrigine, marking the first new type of pain reliever to be approved in over 20 years.The drug, sold under the brand ...

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXtm (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

Neuropathy, a debilitating condition affecting millions worldwide, can significantly impair daily life and well-being. Traditional treatments often fall short, offering temporary relief at best while ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...